Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Open Label Clinical Trial to Assess Efficacy, Safety and Tolerability of Botulinum Toxin A (Xeomin®) in Treatment of Expression Wrinkles in the Upper Third of the Face

NCT00986570 is registered in ClinicalTrials.gov with Biolab Sanus Farmaceutica as lead sponsor.

NCT NCT00986570
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00986570 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Open Label Clinical Trial to Assess Efficacy, Safety and Tolerability of Botulinum Toxin A (Xeomin®) in Treatment of Expression Wrinkles in the Upper Third of the Face
Lead sponsor
Biolab Sanus Farmaceutica
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2009
Completion date
November 30, 2010
Enrollment
121 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

skin aging